Individualization of antiviral treatment regimens for chronic hepatitis C

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 4, 2006, Pages 321-325

  Paulon, Emma ^a   Naoumov, Nikolai V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiviral treatment; Chronic hepatitis C; Hepatitis C virus genotypes; Hepatitis C virus RNA; Pegylated interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; INTERFERON; MACROGOL; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN;

AGE DISTRIBUTION; BODY WEIGHT; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CONJUGATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; FATTY LIVER; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HELPER CELL; HEPATITIS C; HEREDITY; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; MATHEMATICAL MODEL; MONOTHERAPY; PRIORITY JOURNAL; RELAPSE; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 33645098303     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200604000-00003     Document Type: Conference Paper

References (52)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Concales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
4. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients with HCV genotypes 2 or 3. J Hepatol 2004; 40:993-999.
5. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, et al. Peginterferon α-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54:858-866.
6. EASL. International consensus conference on hepatitis C. Consensus statement. J Hepatol 1999; 30:956-961.
7. National Institutes of Health. Consensus Statement on Management of Hepatittis C: 2002. NIH Consens State Sci Statements 2002; 3:1-46.
8. Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, et al. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: virological features of IFN-resistant cases with hepatocyte steatosis. J Med Virol 2005; 75:550-558.
9. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
10. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-107.
11. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26:226-231.
12. 2 Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120:1438-1447.
13. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37:1351-1358.
14. Jessner W, Gschwantler M, Steindl-Munda P, Hofer H, Watkins-Riedel T, Wrba F, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001; 358:1241-1242.
15. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-2617.
16. Tang KH, Herrmann E, Cooksley H, Tatman N, Chokshi S, Williams R, et al. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. J Hepatol 2005; 43:776-782.
17. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346:1006-1007.
18. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98:706-714.
19. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118:346-355.
20. Marinho RT, Pinto R, Santos ML, Lobos IV, Moura MC. Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C. J Viral Hepat 2004; 11:206-216.
21. Reddy KJ, Hoofnagle JH, Tong MJ. Racial differences in response to therapy with interferon in chronic hepatitis C. Hepatology 1999; 30:787-793.
22. Jeffers LJ, Cassidy W, Howell CD. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39:1702-1708.
23. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37:1343-1350.
24. Luo S, Cassidy W, Jeffers L, Reddy KR, Bruno C, Howell CD. Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy. Clin Gastroenterol Hepatol 2005; 3:499-506.
25. Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001; 33:708-712.
26. Wasmuth HE, Werth A, Mueller T, Berg T, Dietrick CG, Geier A, et al. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C. Hepatology 2004; 40:327-334.
27. Knapp S, Yee LJ, Frodsham AJ, Hennig BJ, Hellier S, Zhang L, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003; 4:411-419.
28. Suzuki F, Arase Y, Suzuki Y, Tsubota A, Akuta N, Hosaka T, et al. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat 2004; 11:271-276.
29. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128:1437-1444.
30. Dalgard O, Bjoro K, Helium KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40:1260-1265.
31. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-527.
32. Tabaru A, Narita R, Hiura M, Abe S, Otsuki M. Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a. Am J Gastroenterol 2005; 100:862-867.
33. Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, et al. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis. J Med Virol 2005; 75:550-558.
34. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189:964-970.
35. Brouwer JT, Nevens F, Bekkering FC, Bourgeois N, Van Vlierberghe H, Weegink CJ, et al., for the Benelux Study Group on Treatment of Chronic Hepatitis. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. J Hepatol 2004; 40:689-695.
36. Berg T, von Wagner M, Hinrichsen H, Albrechts C, Heintges T, Buggisch P, et al. Reduction of the relative relapse rate by prolongation of the duration of therapy with peginterferon alfa-2a plus ribavirin in patients with genotype 1 infection up to 72 weeks. Hepatology 2004; 40 (suppl 1):238A.
37. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment virenia. J Hepatol 2005; Nov 7; (Epub ahead of print).
38. Bruno S, Crosignani A, Pinzello GB. Hepatitis C virus genotype 4 and response to combination therapy with interferon-alpha2b plus ribavirin. Ann Intern Med 2000; 133:922-923.
39. el Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O, Ahdy A. Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. J Viral Hepat 1996; 3:261-264.
40. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, et al. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54:858-866.
41. Sangiovanni A, Morales R, Spinzi G, Rumi M, Casiraghi A, Ceriani R, et al. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 1998; 27:853-856.
42. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118:760-764.
43. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le B, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34:1000-1005.
44. Alberti A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J Hepatol 2005; 42:266-274.
45. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127:1724-1732.
46. Wright M, Forton D, Main J, Goldin R, Torok E, Tedder R, et al. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. J Viral Hepat 2005; 12:58-66.
47. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al., and the Tokyo-Chiba Hepatitis Research Group. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142:105-114.
48. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123:483-491.
49. Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53:425-430.
50. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303-1313.
51. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-1680.
52. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al., and the HALT-C Trial Group. Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25:472-492.